<DOC>
	<DOCNO>NCT01137968</DOCNO>
	<brief_summary>The purpose evaluate efficacy safety imetelstat ( GRN163L ) maintenance therapy patient advanced stage NSCLC progress 4 cycle platinum base therapy . Participants randomize 2:1 ratio imetelstat + standard care versus standard care alone . Participants receive bevacizumab induction chemotherapy continue receive bevacizumab study .</brief_summary>
	<brief_title>Imetelstat Maintenance Therapy After Initial Induction Chemotherapy Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Signed informed consent . Ability willingness comply requirement study protocol . Male female , age 18 . Histologically cytologically confirm diagnosis NSCLC Stage IV ( use 7th edition AJCC , wet IIIb / IV use 6th edition ) , recurrent locally advanced disease amenable radiation surgery curative intent amenable concurrent chemoradiation . Patients complete four six cycle platinumbased chemotherapy doublet first line , advance NSCLC , evidence disease progression accord RECIST version 1.1 . Adjuvant chemotherapy great one year prior progression allow . Patients willing able continue treatment bevacizumab , receive platinum base chemotherapy . ECOG performance status 01 Adequate bone marrow reserve measure ANC ≥ 1500/mm3 , hemoglobin ≥ 9 g/dL , platelet count ≥ 75,000 μL . Must measure ≥ 1 week last transfusion blood product and/or last dose hematopoietic growth factor . Prothrombin time ( PT ) INR aPTT ≤ 1.5 x ULN . Serum creatinine &lt; 1.5 mg/dL creatinine clearance &gt; 45 mL/min . Urinalysis &lt; 2+ protein urinary excretion &lt; 2 g protein/day ( patient receive bevacizumab ) . AST ( SGOT ) ALT ( SGPT ) &lt; 2.5 x ULN , ( AST ( SGOT ) ALT ( SGPT ) &lt; 5 x ULN document liver metastasis ) . Serum bilirubin &lt; 2.0 mg/dL ( patient Gilbert 's syndrome : serum bilirubin &lt; 3 x ULN ) . Alkaline phosphatase &lt; 2.5 x ULN ( patient document liver bone metastasis , alkaline phosphatase ≤ 5 x ULN ) . No obvious related major organ toxicity would compromise patient 's ability participate clinical trial novel agent . Patients may receive prior radiation therapy local locally advanced disease provide clinically significant adverse effect associate prior therapy recover Grade 1 less . Women childbearing potential must negative serum pregnancy test agree use effective birth control 12 week last treatment imetelstat . Males must agree use effective birth control partner 12 week last treatment imetelstat . Patients meet follow criterion exclude screen study entry : Patients eligible induction therapy platinum base chemotherapy doublet . Patients receive , schedule receive pemetrexed erlotinib maintenance therapy . Patients receive bevacizumab must recent history hemoptysis ≥ ½ teaspoon red blood history ≥ 2 g/24 hr urine protein receive prior bevacizumab , squamous cell histology . Patients exclude randomize follow criterion apply : Last dose induction chemotherapy &lt; 21 day prior randomization &gt; 42 day prior randomization History pulmonary hemorrhage ( &gt; 1 teaspoon ) within 4 week prior randomization . Antiplatelet therapy within 2 week prior randomization , low dose aspirin prophylaxis therapy . Therapeutic anticoagulation therapy except low dose warfarin ( e.g. , 1 mg mouth per day ) . Radiation therapy within 3 week prior randomization ( palliative radiation therapy allow , provide site bone marrow production , i.e . iliac crest radiation field ) Major surgery within 4 week prior first study drug administration ( central line placement allow ) Active central nervous system ( CNS ) metastatic disease . Patients stable CNS disease follow completion radiation therapy and/or surgery eligible . Any active malignancy Active chronically recurrent bleeding ( e.g. , active peptic ulcer disease ) Clinically significant infection Active autoimmune disease require immunosuppressive therapy Clinically significant cardiovascular disease condition include : Congestive heart failure ( CHF ) require therapy Need antiarrhythmic therapy ventricular arrhythmia Severe conduction disturbance Angina pectoris require therapy Medically uncontrolled hypertension per Investigator 's discretion Myocardial infarction within 6 month prior first study drug administration New York Heart Association Class II , III , IV cardiovascular disease Any severe , acute , chronic medical psychiatric condition , laboratory abnormality , difficulty comply protocol requirement may increase risk associate study participation study drug administration may interfere interpretation study result , judgment Investigator , would make patient inappropriate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>imetelstat</keyword>
	<keyword>imetelstat sodium</keyword>
	<keyword>GRN163L</keyword>
	<keyword>telomerase inhibitor</keyword>
	<keyword>telomerase inhibition</keyword>
	<keyword>maintenance therapy</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>relapse non-small cell lung cancer</keyword>
	<keyword>advanced non-small cell lung cancer</keyword>
	<keyword>NSCLC , cancer stem cell</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>post induction chemotherapy</keyword>
</DOC>